Crisaborole

Drug Profile

Crisaborole

Alternative Names: AN-2728; Crisaborole ointment 2%; Eucrisa; PF-06930164

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Heterocyclic bicyclo compounds; Nitriles; Nonsteroidal anti-inflammatories; Organic boron compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Atopic dermatitis
  • Suspended Psoriasis

Most Recent Events

  • 14 Dec 2016 Registered for Atopic dermatitis (In adolescents, In children, In adults, In the elderly) in USA (Topical) - First global approval
  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 22 Mar 2016 PDUFA action date of 07/01/2017 assigned by FDA for Crisaborole for Atopic dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top